Biotech

All Articles

Despite blended market, an equity capital revival may be coming in Europe: PitchBook

.While the biotech investment performance in Europe has decreased somewhat adhering to a COVID-19 fu...

8 months after a $213M fundraise, gene editor Volume produces reduces

.After increasing $213 million in 2023-- among the year's most extensive personal biotech rounds-- T...

BioMarin builds director staff along with biotech vets-- Chutes &amp Ladders

.Invite to this week's Chutes &amp Ladders, our summary of considerable leadership hirings, firings ...

Biopharma Q2 VC reached highest degree since '22, while M&ampA slowed down

.Equity capital funding into biopharma cheered $9.2 billion throughout 215 handle the 2nd one-fourth...

Bicara, Zenas find IPOs to drive late-phase properties toward market

.Bicara Rehabs as well as Zenas Biopharma have actually offered clean inspiration to the IPO market ...

Genentech to shut cancer cells immunology investigation department

.Genentech is going to shut its own cancer immunology study division, and unit mind and well-known t...

Kezar goes down strong growth however to verify its well worth in phase 1 test

.Kezar Lifestyle Sciences is actually dropping its unpromising period 1 sound cyst medicine as the b...

Acelyrin loses izokibep, dismisses 3rd of team

.Regardless of izokibep preserving its newfound winning streak in the clinic, Acelyrin is no longer ...

Rivus' period 2 obesity-related heart failure test attacks endpoint

.Rivus Pharmaceuticals has actually plumped up the customers of its fat-busting, muscle-sparing medi...

Ovid standstills preclinical work, IV plan after soticlestat stop working

.Ovid Rehab presently showed final month that it was actually trimming back its head count as the fi...